Literature DB >> 10579476

The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients.

A G Johnson1, R J Rigby, P J Taylor, C E Jones, J Allen, K Franzen, M C Falk, D Nicol.   

Abstract

BACKGROUND: Mycophenolic acid kinetics have been reported to vary after renal transplantation, and mycophenolic acid area under the concentration-time curve (AUC) is the best predictor of suppression of graft rejection.
METHODS: To determine whether mycophenolic acid kinetics vary after renal transplantation and to examine the potential role of enterohepatic recirculation, we investigated the kinetics of mycophenolic acid and mycophenolic acid glucuronide on days 2, 5, and 28 after transplantation in 10 kidney transplant recipients (male/female ratio, 1.5; mean age, 41.7 +/- 5.0 years) given 1 g mycophenolate mofetil twice a day. To facilitate therapeutic drug monitoring, we examined a limited sampling strategy for estimating 12-hour mycophenolic acid [AUC(0-12)].
RESULTS: The mean +/- SE AUC(0-12) for mycophenolic acid on day 28 was 38.5 +/- 1.6 mg x h/L, with a secondary peak 4 to 8 hours after dosing that was attributable to enterohepatic recirculation. Marked variability was shown in the kinetic profile of mycophenolic acid among patients across the three sampling days. Mycophenolic acid AUC(0-12) was positively predicted by both serum creatinine (P = .01) and serum albumin (P = .03) but not by time after transplantation, body weight, or trough concentration. Limited sampling (at 0, 1, 3, and 6 hours) accounted for 84.1% of the variability in the mycophenolic acid AUC(0-12) data and predicted the AUC(0-12) closely (r2 = 0.954) when evaluated in 10 different kidney transplant recipients.
CONCLUSIONS: Mycophenolic acid AUC(0-12) is predicted by serum albumin and creatinine after kidney transplantation, and the AUC(0-12) may be determined during the early posttransplant period while the patient remains hospitalized with use of a limited sampling strategy to facilitate therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579476     DOI: 10.1016/S0009-9236(99)70012-3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients.

Authors:  Hao Chen; Chenghong Peng; Zhicheng Yu; Baiyong Shen; Xiaxing Deng; Weihua Qiu; Yue Fei; Chuan Shen; Guangwen Zhou; Weiping Yang; Hongwei Li
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.

Authors:  Takayuki Katsuno; Takenori Ozaki; Takaya Ozeki; Asaka Hachiya; Hangsoo Kim; Noritoshi Kato; Takuji Ishimoto; Sawako Kato; Tomoki Kosugi; Naotake Tsuboi; Masashi Mizuno; Yasuhiko Ito; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2018-05-23       Impact factor: 2.801

5.  Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.

Authors:  Christine E Staatz; Stephen B Duffull; Bryce Kiberd; Albert D Fraser; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2005-07-28       Impact factor: 2.953

Review 6.  Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?

Authors:  Michel Mourad; Pierre Wallemacq; Josiane König; Evelyne Henry de Frahan; Djamila Chaib Eddour; Martine De Meyer; Jacques Malaise; Jean Paul Squifflet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.

Authors:  Xiao-Yang Lu; Hong-Feng Huang; Jian-Zhong Sheng-Tu; Jian Liu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

8.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

10.  Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.

Authors:  Reinier M van Hest; Teun van Gelder; Arnold G Vulto; Leslie M Shaw; Ron A A Mathot
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.